Abliva Ab
Abliva discovers and develops medicines for the treatment of mitochondrial diseases. These rare and often very severe diseases occur when the cell’s energy provider, the mitochondria, do not function properly. The company has prioritized two projects. a powerful regulator of the essential co-enzymes NAD⁺ and NADH, has entered late-stage development. NV354, an energy replacement therapy, has completed preclinical development. Abliva, based in Lund, Sweden, is listed on Nasdaq Stockholm, Sweden (ticker: ABLI).
7-day free trial · no credit card
Verified contacts
5
available on Kipplo
LinkedIn employees
13
1 to 10 range
Open roles
—
no listings
Distinct roles
5
indexed titles
Tech stack
1
tools in use
Monthly traffic
260
organic / mo
Sign up free to see all 5 verified contacts at Abliva Ab
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
5 contacts with verified email or phone · masked until revealed.
- DN
Dag Nesse
Vice President Clinical Operations · Other
EmailPhone - EE
Eskil Elmér
CSO · General Business & Management
EmailPhone - MH
Magnus Hansson
Chief Medical Officer · Healthcare & Human Services
EmailPhone
Showing 3 of 5 verified contacts
Top roles at Abliva Ab
5 distinct titles indexed · top 5 shown.
- 1chief medical officer
- 1communications officer & lab manager
- 1cso
- 1ekonomiassistent
- 1vice president clinical operations
Sign up to unlock all 5 contacts at Abliva Ab
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 5 verified contacts at Abliva Ab
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.